Status message

Not the entire site translated, but only to "Journal"

Modern Possibilities of Therapeutic Correction of Antipsychotics-Induced Hyperprolactinemia

Mazo G.E.1, Kibitov A.O.1,2
1 Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint-Petersburg, Russian Federation
2 Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation

Hyperprolactinemia (GPRL) is one of the most common side effects when prescribing antipsychotic therapy. GPRL is obviously a significant problem in psychiatric clinical practice. A significant effect of increasing prolactin levels on the somatic state of patients, as well as on the course of the disease process, necessitates a change in treatment tactics to correct GPRL. Currently, methods have been developed to reduce prolactin levels with the use of antipsychotics.
The purpose of this article is to evaluate current therapeutic options for reducing the negative effects of antipsychotics-induced hyperprolactinemia. Correction methods associated with the use of additional drugs that reduce prolactin levels, or correcting the clinical manifestations of increased prolactin are currently being studied and there is no convincing data on their safety in this category of patients. The most acceptable and having a real broad perspective in everyday clinical practice approach is the replacement of antipsychotics with a drug with less prolactogenic activity.
The data presented in the article on the lesser prolactogenic activity of prolonged forms of second-generation antipsychotics open up new perspectives in the correction of antipsychotics-induced hyperprolactinemia when the active substance does not change, but only the administration form, which makes it possible to assume a decrease in the risks associated with drug replacement.
Key words: schizophrenia, antipsychotics, hyperprolactinemia, prolonged forms of antipsychotics

Contact: galina-mazo@yandex.ru
Citation: Mazo G.E., Kibitov A.O. Modern Possibilities of Therapeutic correction of Antipsychotics-Induced Hyperprolactinemia // Sovrem. ter. psih. rasstrojstv. – 2020. – Vol. 1. – P. 29-36. DOI: 10.21265/PSYPH.2020.42.11.004 
 

References

1.    Bobes J., Sáiz Ruiz J., Manuel Montes J., Mostaza J., Rico-Villademoros F., Vieta E. Spanish consensus on physical health of patients with bipolar disorder // Rev Psiquiatr Salud Ment. – 2008. – Vol. 1. – P. 26–37. 
2.    Giner J., Saiz Ruiz J., Bobes J., Zamorano E., López F., Hernando T., et al., Spanish consensus on the physical health of patients with depressive disorders // Rev Psiquiatr Salud Ment. – 2014. – Vol. 7. – P. 195–207.
3.    Fagiolini A., Montejo A.L., Thomas P., Millar H. Physical health considerations in psychiatry: views on recognition, monitoring and management // Eur Neuropsychopharmacol. – 2008. – Vol. 18, Suppl. 2. – P. 10. 
4.    Montejo A.L. Prolactin awareness: an essential consideration for physical health in schizophrenia // Eur Neuropsychopharmacol. – 2008. – Vol. 18, Suppl. 2. – P. 101–130.
5.    Laita P., Cifuentes A., Doll A., Llorente C., Cortés I., Parellada M. et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents // J Child Adolesc Psychopharmacol. – 2007. –Vol. 17. – P. 487–502.
6.    Bushe C., Shaw M., Peveler R. A review of the association between antipsychotic use and hyperprolactinaemia // J Psychopharmacol. – 2008. –Vol. 22. – P. 46–55. 
7.    Cookson J., Hodgson R., Wildgust H.J., Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis // J Psychopharmacol. – 2012. – Vol. 26. – P. 42–51. 
8.    Ignacak A., Kasztelnik M., Sliwa T., Korbut R., Rajda K., Guzik T. Prolactin not only lactotrophin. A ‘‘new’’ view of the ‘‘old’’ 
hormone // J Physiol Pharmacol. – 2012. – Vol. 63. – P. 435–443.
9.    Melmed S., Casanueva F.F., Hoffman R.A., Kleinberg L.D., Montori M.V., Schlechte A.J. et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline // J Clin Endocrinol Metab. – 2011. – Vol. 96. – P. 273–288.  
10.    Mazo G.E., Gorobets L.N. Oslozhneniya neirolepticheskoi giperprolaktinemii // Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. – 2018. – № 2. – S. 104–108.
11.    Holt R.I., Peveler R.C. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management // Clin Endocrinol (Oxf.). – 2011. – Vol. 74. – P. 141–147.
12.    Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia // Aust N Z J Psychiatry. – 2011. – Vol. 45. – P. 830–837. 
13.    Bostwick J.R., Guthrie S.K., Ellingrod V.L. Antipsychotic-induced hyperprolactinemia // Pharmacotherapy. – 2009. – Vol. 29. – P. 64–73. 
14.    Volavka J., Czobor P., Cooper T.B., Sheitman B., Lindenmayer J.P., Citrome L. et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol // J Clin Psychiatry. – 2004. – Vol. 65. – P. 57–61.
15.    Shahin Akhondzadeh, Farzin Rezaei, Bagher Larijani et al. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia // Schizophrenia Research. – 2006. – Vol. 84. – P. 405–410.
16.    Halbreich U., Kahn L.S Hormonal aspects of schizophrenias: an overview // Psychoneuroendocrinology. – 2003. – Suppl. 2. – P. 1–16.
17.    Mazo G.E. Perspektivy razvitiya endokrinologicheskoi psikhiatrii // Sb. nauch. tr. «Sovremennye dostizheniya v diagnostike i lechenii endogennykh psikhicheskikh rasstroistv». – SPb., 2008. – S. 210–224. 
18.    Peuskens J., Pani L., Detraux J., De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review // CNS Drugs. – 2014. – Vol. 28, No. 5. – P. 421–453. – DOI: 10.1007/s40263-014-0157-3
19.    Reavley A., Fisher A.D., Owen D. Psychological distress in patients with hyperprolactinaemia // Clin Endocrinol. – 1997. – Vol. 47. – P. 343–347. 
20.    Mazo G.E. Vliyanie depressii na techenie shizofrenii // Psikhiatriya i psikhofarmakoterapiya. – 2006. – T. 8, № 3. – S. 22–24. 
21.    Mazo G.E., Nikiforova Yu.S., Shchedrina L.V. Vliyanie depressii pri shizofrenii na uroven' BDNF // Psikhiatriya i psikhofarmakoterapiya. – 2015. – № 1. – S. 12–17. 
22.    Reine G., Lancon C., Di Tucci S. et al. Depression and subjective quality of life in chronic phase schizophrenic patients // Acta Psychiatr. Scand. – 2003. – Vol. 108, No. 4. – P. 297–303. 
23.    Dedov I.I., Mel'nichenko G.A., Romantsova T.I. Sindrom giperprolaktinemii. – M.; Tver': OOO Izdatel'stvo «Triada», 2004. – 304 s.
24.    Kell R., Buckman M.T., Fava M. et al. Prolactin, aggression and hostility: a discussion of recent studies // Psychiatr Dev. – 1984. – Vol. 2. – P. 131–138.
25.    Mazo G.E., Bubnova Yu.S. Depressiya pri shizofrenii: diagnostika i terapiya // Zhurnal nevrologii i psikhiatrii imeni C.C. Korsakova. – 2013. – T. 113, № 3–1. – S. 90–93.
26.    Keks N.A., Copolov D.L., McKenzie D.P., Kulkarni J., Hill C., Hope J.D., Singh B.S. Basal and haloperidol-stimulated prolactin and symptoms of non-affective and affective psychoses in neuroleptic-free men // Biological Psychiatry. – 1995. – Vol. 37. – P. 229–234. 
27.    Tandon R., Halbreich U. The second-generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroendocrine side effects // J Psychoneuroendocrinology. – 2003. – Vol. 28, Suppl. 1. – P. 1–7. 
28.    Bubnova Yu.S., Dorofeikov V.V., Mazo G.E., Petrova N.N. K voprosu o mekhanizmakh razvitiya depressii pri shizofrenii // Psikhiatriya i psikhofarmakoterapiya. – 2012. – T. 14, № 4. – S. 21–26.
29.    Henry J.F., Sherwin B.B. Hormones and cognitive functioning dur- ing late pregnancy and postpartum: a longitudinal study // Behav Neurosci. – 2012. – Vol. 126. – P. 73–85.
30.    Moffat S.D., Zonderman A.B., Metter E.J., Blackman M.R., Harman S.M., Resnick S.M. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men // J Clin Endocrinol Metab. – 2002. – Vol. 87. – P. 5001–5007.
31.    Basson R., Rees P., Wang R.X., Montejo A.L., Incrocci L. Sexual function in chronic illness // J Sex Med. – 2010. – Vol. 7, No. 1, Pt. 2. – P. 374–388. 
32.    Montejo A.L, Majadas S., Rico-Villademoros F., Llorca G., de la Gándara J., Franco M. et al. Frequency of sex- ual dysfunction in patients with a psychotic disorder receiving antipsychotics // J Sex Med. – 2010. – Vol. 7. – P. 3404–3413.
33.    Gorobets L.N., Mazo G.E. Giperprolaktinemiya pri ispol'zovanii antipsikhotikov vtorogo pokoleniya: printsipy profilaktiki, diagnostiki i korrektsii // Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. – 2017. – № 1. – S. 63–70.
34.    Gorobets L.N., Mazo G.E. Neiroendokrinnye disfunktsii pri ispol'zovanii psikhofarmakoterapii: klinika, diagnostika, faktory riska i korrektsiya // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2014. – № 10. – C. 85–93.
35.    Montejo Á.L., Arango C., Bernardo M., Carrasco J.L., Crespo-Facorro B., Cruz J.J., Pino-Montes J.D., García-Escudero M.A., García-Rizo C. et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics // Frontiers in Neuroendocrinology. – 2017. – Vol. 45. – P. 25–34.
36.    Halperin I., Cámara R., García M., Ollero D. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia // Endocrinol Nutr. – 2013. – Vol. 60. – P. 308–319.
37.    Mitsonis C.I., Mitropoulos P.A., Dimopoulos N.P., Kararizou E.G., Psarra V.V., Tsakiris F.E. et al. Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study // J Clin Psychiatry. – 2008. – Vol. 69. – P. 206–212.
38.    Peveler R.C., Branford D., Citrome L., Fitzgerald, P., Harvey, P.W., Holt, R.I.G. et al. Antipsychotics and hyperprolactinaemia: clinical recommendations // J Psychopharmacol. – 2008. – Vol. 22. – P. 98–103.
39.    Gorobets L.N., Mazo G.E. Medikamentoznaya korrektsiya neirolepticheskoi giperprolaktinemii // Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. – 2017. – № 2. – S. 79–85.
40.    Lee M.S., Song H.C., An H., Yang J., Ko Y.H., Jung I.K., Joe S.H. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study // Psychiatry Clin Neurosci. – 2010. – Vol. 64. – P. 19–27. 
41.    Santos Nunes V., El Dib R., Boguszewski C.L., Nogueira C.R., Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis // Pituitary. – 2011. – Vol. 14. –P. 259–265.
42.    Chang S.C., Chen C.H., Lu M.L. Cabergoline-induced psychotic exacerbation in schizophrenic patients // Gen Hosp Psychiatry – 2008. – Vol. 30. – P. 378–380. 
43.    Hashimoto K., Sugawara N., Ishioka M., Nakamura K., Yasui-Furukori N., The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study // Neuropsychiatr Dis Treat. – 2014. – Vol. 10. – P. 1571–1576.
44.    Andersohn F., Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists // Mov Disord. – 2009. – Vol. 15, No. 24. – P. 129–133.
45.    Huhn M., Nikolakopoulou A., Schneider-Thoma J., Krause M., Samara M., Peter N., Arndt T., Bäckers L., Rothe P., Cipriani A., Davis J., Salanti G., Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis // Lancet. – 2019. – Vol. 394, No. 10202. – P. 939–951. – DOI: 10.1016/S0140-6736(19)31135-3
46.    Chwieduk C.M., Keating G.M. Paliperidone extended release: a review of its use in the management of schizophrenia // Drugs. – 2010. – Vol. 70. – P. 1295–1317.
47.    Besnard I., Auclair V., Callery G., Gabriel-Bordenave C., Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance // Encephale. – 2014. – Vol. 40. – P. 86–94.
48.    Arakawa R., Okumura M., Ito H., Takano A., Takahashi H., Takano H. 
et al. Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia // J Clin Psychiatry. – 2010. – Vol. 71. – P. 1131–1137.
49.    Fleischhacker W.W., Hofer A., Hummer M. Managing Schizophrenia: The Compliance Challenge. Second edition. London, 2008. 50 p.
50.    Kelly D.L., Wehring H.J., Earl A.K., Sullivan K.M., Dickerson F.B., Feldman S., McMahon R.P., Buchanan R.W., Warfel D., Keller W.R., Fischer B.A., Shim J.C. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin) // BMC Psychiatry. – 2013. – Vol. 13. – P. 214. – DOI: 10.1186/1471-244X-13-214 
51.    Kuloglu M., Ekinci O., Albayrak Y., Caykoylu A. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature // Arch Womens Ment Health. – 2010. – Vol. 13. – P. 443–447.
52.    Grande I., Bernardo M., Bobes J., Saiz-Ruiz J., Alamo C., Vieta E. Antipsychotic switching in bipolar disorders: a systematic review // Int J Neuropsychopharmacol. – 2014. – Vol. 17. – P. 497–507.
53.    Mazo G.E., Gorobets L.N. Zamena antipsikhotika kak metod predotvrashcheniya formirovaniya rezistentnosti pri shizofrenii // Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. – 2017. – № 3. – S. 74–80.
54.    Bernardoa M., Vieta E., Saiz Ruiz J., Rico-Villademoros F., Álamo C., Bobes J., Grupo RECAP Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry // Rev Psiquiatr Salud Ment (Barc.). – 2011. – Vol. 4. – P. 150–168. – DOI: 10.1016/j.rpsm.2011.07.003 
55.    Nakamura M., Nagamine T., Sato G., Besho K. Prolactin Levels After Switching to Paliperidone Palmitate in Patients with Schizophrenia // Innov Clin Neurosci. – 2016. – Vol. 13, No. 5–6. – P. 28–30. 
56.    Fernández-Miranda J.J., Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia // Int Clin Psychopharmacol. – 2017. – Vol. 32, No. 1. – P. 6–12. 
57.    Misawa F., Kishimoto T., Hagi K., Kane J.M., Correll C.U. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics // Schizophr Res. – 2016. – Vol. 176, No. 2–3. – P. 220–230. – DOI: 10.1016/j.schres.2016.07.018
58.    de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics // Neuropharmacology. – 2019. – Vol. 28, No. 107656. – DOI: 10.1016/j.neuropharm.2019.05.033  
59.    Nakamura M., Fujita Y., Nagamine T. Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient // Asia Pac Psychiatry. – 2018. – Vol. 10, No. 1. – DOI: 10.1111/appy.12300 
60.    Kibitov A.O., Mazo G.E. Metabolicheskie pobochnye effekty atipichnykh antipsikhotikov: mezhindividual'naya variabel'nost' i geneticheskii risk // Sotsial'naya i klinicheskaya psikhiatriya. – 2018. –  № 1. – S. 90–100.
61.    Gorobets L.N., Litvinov A.V., Bulanov V.S., Mazo G.E. Sovremennye vzglyady na diagnostiku neirolepticheskoi giperprolaktinemii // Rossiiskii psikhiatricheskii zhurnal. – 2018. – № 4. – S. 56–63. 
62.    Kibitov A.O., Ivashchenko D.V., Sychev D.A. Farmakogeneticheskii podkhod k povysheniyu effektivnosti i bezopasnosti antipsikhoticheskoi farmakoterapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2017. – № 1. – S. 2–13.
63.    Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., Eap C.B. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort // Clin Pharmacokinet. – 2015. – Vol. 54, No. 12. – P. 1259–1272. – DOI: 10.1007/s40262-015-0289-8
64.    Korchagina N.Yu., Mazo G.E., Kibitov A.O. Farmakogeneticheskii test v praktike vracha-psikhiatra: algoritm prinyatiya reshenii i terapevticheskaya taktika na primere klinicheskogo sluchaya // Sotsial'naya i klinicheskaya psikhiatriya. – 2019. – № 2. – S. 51–58.
65.    Yoo H.D., Cho H.Y., Lee S.N., Yoon H., Lee Y.B. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1 // J Pharmacokinet Pharmacodyn. – 2012. – Vol. 39, No. 4. – P. 329–341. – DOI: 10.1007/s10928-012-9253-5
66.    Nesvåg R., Hendset M., Refsum H., Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication // Acta Psychiatr Scand. – 2006. – Vol. 114, No. 1. – P. 21–26.
67.    El-Mallakh R.S., Watkins J. Prolactin Elevations and Permeability Glycoprotein // Prim Care Companion CNS Disord. – 2019. – Vol. 21, No. 3. – Pii: 18nr02412. – DOI: 10.4088/PCC.18nr02412
68.    Nasrallah H.A. Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality // Schizophrenia Research. – 2018. – Vol. 197. – P. 69–70. – DOI: 10.1016/j.schres.2018.02.004